Wat zijn uw favoriete aandelen voor het najaar?
Stem op BEL20 aandelen / Stem op AEX aandelen


Celyad (voorheen Cardio3 BioSciences SA)

Beleggen, aandelen kopen in België, informatie, koersen en analyses

Gebruikersavatar
Daniël
Premiummember
Premiummember
Berichten: 986
Lid geworden op: 08 sep 2012 08:46
Locatie: Earth
waarderingen: 180
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door Daniël »

Brief van Celyad aan de aandeelhouders
https://www.celyad.com/files/library/Ac ... -final.pdf
And its gone! liked last!





Volg Beursig.com op Twitter en Facebook

     


Gebruikersavatar
Daniël
Premiummember
Premiummember
Berichten: 986
Lid geworden op: 08 sep 2012 08:46
Locatie: Earth
waarderingen: 180
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door Daniël »

Tweet van Celyad

Celyad is listed in the top 20 EU immuno-oncology companies that are fighting cancer !

Niet te zien aan de koers :roll:

beursfre
Forum actieveling
Forum actieveling
Berichten: 293
Lid geworden op: 02 mar 2018 15:26
waarderingen: 61
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door beursfre »

Daniël schreef:
26 feb 2020 09:16
Tweet van Celyad

Celyad is listed in the top 20 EU immuno-oncology companies that are fighting cancer !

Niet te zien aan de koers :roll:
mss wel
anders was er mss 15 vanaf....
Biocartis (5,04€) - IBA (9,00€) - Inventiva (5,14€) - MDX (0,789€) - Mithra (20,05€) - Orange BE (14,90€) - Pharming (1,02€) - Exmar (2,10€) - Ontex (11,50€) - Telenet (33,96€) - Gensight Biologics (2,94€) - Acacia Pharma (2.07€) - Ageas (35,99€) - Innate Pharma (3,75€)

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1488
Lid geworden op: 17 sep 2014 14:20
waarderingen: 626
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door Munnybunny »

Beetje gekocht aan 7,90...

vlere
Forum actieveling
Forum actieveling
Berichten: 263
Lid geworden op: 06 mar 2017 16:04
waarderingen: 113
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door vlere »

Starten we de dag onder de 4€? Vraag mij af wanneer de volledige beursgang terug hersteld gaat zijn na de corona aanval. :?

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 772
Lid geworden op: 30 mei 2018 21:25
waarderingen: 337
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door And its gone! »

BRIEF-Celyad Reports Full Year 2019 Financial Results And Provides Business Update
01:02 (25/03) - Bron: Reuters
Celyad SA CYAD.BR :
* CELYAD REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND
PROVIDES
BUSINESS UPDATE
* NKG2D CAR-T CLINICAL CANDIDATE CYAD-01 CONTINUES TO
ADVANCE IN
PHASE 1 TRIALS FOR TREATMENT OF PATIENTS WITH R/R AML OR MDS
* CELYAD -CO NOT CURRENTLY EXPERIENCING ANY MAJOR
DISRUPTIONS IN
ITS BUSINESS RELATED TO COVID-19

Source text for Eikon:
Further company coverage: CYAD.BR
Celyad Reports Full Year 2019 Financial Results and Provides Business Update

First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
CYCLE-1 trial of autologous CYAD-02 for the treatment of r/r AML and MDS ongoing
Expansion cohort of alloSHRINK trial evaluating allogeneic CYAD-101 for metastatic colorectal cancer (mCRC) on target to begin in second half 2020
Submission of IND for short hairpin RNA (shRNA)-based allogeneic CYAD-211 candidate for multiple myeloma (MM) expected in mid-2020
Treasury position of €39.3 million ($44.0 million) as of December 31, 2019

MONT-SAINT-GUIBERT, Belgium, March 24, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced its consolidated financial results for fiscal year 2019 ended December 31, 2019 and provided a business update.

“This is an exciting time for us as we advance Celyad as an innovative leader in the industry which is focused on developing CAR-T therapies for cancer patients. The progress we made throughout 2019 positions Celyad with a balanced pipeline of clinical and preclinical CAR-T candidates as we enter the new decade with several milestones on the horizon,” commented Filippo Petti, Chief Executive Officer of Celyad. “We now have two autologous clinical CAR-T candidates in development for the treatment of r/r AML and MDS and a portfolio of promising allogeneic CAR-T candidates, led by CYAD-101, for the treatment of mCRC. We look forward to providing key updates on our clinical progress throughout 2020. Over the past year, we also progressed our shRNA platform for next-generation CAR-T candidates, including our preclinical allogeneic BCMA-targeted candidate, CYAD-211. I am extremely proud of our team’s achievements over the past twelve months and look forward to a productive 2020.”

Recent Business Highlights and Pipeline Updates

CYAD-01 – Autologous NKG2D CAR-T for r/r AML and MDS
The Company’s lead NKG2D CAR-T clinical candidate CYAD-01 continues to advance in Phase 1 trials for the treatment of patients with r/r AML or MDS. In December 2019, the Company presented the latest data from the CYAD-01 Phase 1 THINK and DEPLETHINK clinical trials at the American Society of Hematology annual meeting. In February 2020, the Company began recruitment in the expansion cohort of the THINK trial evaluating CYAD-01 as a monotherapy. Both the expansion cohort of the THINK trial and the dose-escalation DEPLETHINK trial are now assessing CYAD-01 produced with the Company’s proprietary OptimAb manufacturing process.

CYAD-02 – Autologous NKG2D CAR-T for r/r AML and MDS
In January 2020, the Company announced the first patient has been dosed in the Phase 1 dose-escalation CYCLE-1 trial evaluating the next-generation NKG2D-based CAR-T candidate for the treatment of r/r AML and MDS. The CYCLE-1 trial will evaluate the safety and clinical activity of a single infusion of CYAD-02 produced with the OptimAb manufacturing process following preconditioning chemotherapy with cyclophosphamide and fludarabine. The trial will evaluate three dose levels of CYAD-02 up to one billion cells per infusion.

CYAD-101 – Allogeneic TIM-based, NKG2D CAR-T for mCRC
The Company’s allogeneic NKG2D CAR-T clinical candidate CYAD-101, which incorporates the non-gene edited T-cell receptor Inhibitory Molecule (TIM) technology, continues to advance in the dose-escalation alloSHRINK trial assessing the safety and clinical activity of CYAD-101 administered concurrently with FOLFOX chemotherapy in patients with r/r mCRC. In November 2019, preliminary data from the ongoing alloSHRINK trial were presented at the Society for Immunotherapy of Cancer annual meeting and showed no clinical evidence of Graft-versus-Host Disease post-infusion of CYAD-101. In addition, encouraging anti-tumor activity with two out of 12 patients experiencing a partial response and five patients experiencing stable disease with a minimum of three months of duration. Based on the preliminary data from the Phase 1 alloSHRINK trial, the Company plans to expand the trial to confirm initial safety and clinical activity of CYAD-101 with chemotherapy in refractory mCRC patients.

CYAD-211 – Allogeneic shRNA-based, BCMA CAR-T for r/r MM
The Company continues to pursue the development of the proprietary non-gene edited allogeneic shRNA SMARTvector platform through the CYAD-200 series of product candidates. The Company’s lead preclinical CAR-T candidate from the series, CYAD-211, targets B-cell maturation antigen (BCMA) for the treatment of relapsed / refractory multiple myeloma (r/r MM). The Company continues to progress towards submitting an Investigational New Drug (IND) application for CYAD-211.

Update on COVID-19 Pandemic

In light of the outbreak of the novel coronavirus, COVID-19, the Company has implemented strong measures to help prevent the spread of the virus and protect our employees. In addition, we have put into practice our business continuity plan to minimize the impact on our operations. While the Company is not currently experiencing any major disruptions in its business related to COVID-19, given the recent developments associated with the virus both in Belgium and in the United States and due to recently adopted government policies, the Company does anticipate enrollment delays within our r/r AML and MDS program. The Company is continuing to monitor the impact of COVID-19 on both our clinical and non-clinical planned milestones below and will adjust accordingly as the pandemic continues to rapidly evolve.

Upcoming Milestones

Report additional data from the dose-escalation segment of the CYAD-101 alloSHRINK Phase 1 trial during the second quarter of 2020
Submit IND application for an shRNA-based allogeneic BCMA CAR-T candidate, CYAD-211, for the treatment of patients with r/r MM by mid-2020
Report preliminary data from expansion cohort of the Phase 1 THINK and dose-escalation Phase 1 DEPLETHINK trials evaluating CYAD-01 produced with OptimAb manufacturing process during second half of 2020, due to enrollment delays caused by the COVID-19 pandemic
Begin expansion segment of the CYAD-101 alloSHRINK Phase 1 trial during the second half of 2020
Report preliminary data from the dose-escalation Phase 1 CYCLE-1 trial for CYAD-02 by year-end 2020
2019 Financial Results

As of December 31, 2019, Celyad had a treasury position of approximately €39.3 million ($44.0 million). The Company expects that the existing treasury position will be sufficient, based on the current scope of activities, to fund operating expenses and capital expenditure requirements through the first half of 2021.


Key financial figures for full-year 2019, compared with full-year 2018, are summarized below:

Selected key financial figures (€ millions) Full-Year 2019 Full-Year 2018
Revenue - 3.1
Research and Development expenses (25.2 ) (23.6 )
General and Administrative expenses (9.1 ) (10.4 )
Other income/(expenses) 5.4 (7.3 )
Operating loss (28.9 ) (38.2 )
Loss for the year (28.6 ) (37.4 )
Net cash used in operations (28.2 ) (27.2 )
Treasury position(1) 39.3 49.7
(1) Treasury position’ is an alternative performance measure determined by adding Short-term investments and Cash and cash equivalents from the statement of financial position prepared in accordance with IFRS.

The Company’s license and collaboration agreements generated no revenue for the year ended December 31, 2019, compared to €3.1 million for the year ended December 31, 2018.

Research and development expenses were €25.2 million for the year ended December 31, 2019, compared to €23.6 million for the year ended December 31, 2018. The €1.6 million increase was primarily driven by spending related to the Company’s preclinical product candidates and its investments in process development, scale-up and automation of its manufacturing processes.

General and administrative expenses were €9.1 million for the year ended December 31, 2019, compared to €10.4 million for the year ended December 31, 2018. The difference of €1.3 million was primarily due to the decrease of non-cash expense associated with the vesting of warrants and lower consulting fees for the period.

The Company’s other income/other expenses mainly include:

Non-cash expenses relating to liability reassessment, required by International Financial Reporting Standards (IFRS), associated with the advancement in the Company’s NKG2D CAR-T candidates. Overall, the Company posted €0.3 million in net profit for the year ended December 31, 2019, compared to a net loss of €6.6 million for the year ended December 31, 2018;
Government grant income of €3.3 million for the year ended December 31, 2019, primarily due to new grants from the Walloon Region received in the fourth quarter of 2019, compared to grant income of €0.8 million for the year ended December 31, 2018;
R&D tax credit, recognized as income, of €1.6 million for the year ended December 31, 2019, compared to income of €0.3 million for the year ended December 31, 2018.
Net loss was €28.6 million, or €(2.29) per share, for the year ended December 31, 2019, compared to a net loss of €37.4 million, or €(3.36) per share, for the same period in 2018. The decrease in net loss between periods was primarily due to the increase in net other income.

Net cash used in operations, which excludes non-cash effects, for the year ended December 31, 2019 amounted to €28.2 million, compared to €27.2 million for the same period in 2018. The difference was driven primarily by an increase in spend associated with Research and Development described above.

Annual Report 2019

The Annual Report for the year ended December 31, 2019 will be published tomorrow, March 25, 2020, and will be available on the Company’s website, www.celyad.com. The Company’s statutory auditor, BDO Réviseurs d’Entreprises SCRL (BDO), has confirmed that the completed audit has not revealed any material misstatement in the consolidated financial statements. BDO also confirmed that the accounting data reported in the press release are consistent, in all material respects, with the consolidated financial statements from which it has been derived.

Conference Call and Webcast Details

A conference call will be held on Wednesday, 25 March at 1:00 p.m. CET / 8:00 a.m. ET to review the financial and operating results for full year 2019. Please dial-in five to ten minutes prior to the call start time using the number and conference ID below:

Conference ID: 1392585
International: +44 (0) 2071 928501
Belgium +32 (0) 24 01 70 35
France +33 (0)1 76 72 89 28
Netherlands + 31 (0) 20 71 88 527
United States: +1 917 720 0181



Financial Calendar

Annual shareholders meeting May 5, 2020
First quarter 2020 business update May 7, 2020
Half-year results 2020 August 6, 2020
Third quarter 2020 business update November 10, 2020



johnnybeurs liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 772
Lid geworden op: 30 mei 2018 21:25
waarderingen: 337
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door And its gone! »

Celyad: 'Vertraging bij enkele klinische onderzoeken'
Biotechbedrijf Celyad waarschuwt dat de recrutering van patiënten voor twee klinische onderzoeken vertraging oplopen door de maatregelen die overheden treffen in het kader van Covid-19. Eerder maakte ook Galagapos daar melding van.

Celyad eindigde vorig jaar met 39 miljoen euro op de bankrekening en zegt daat nog mee voort te kunnen tot in het eerste semester van volgend jaar.
Bron: De Tijd 25/03
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Stephan
Forum actieveling
Forum actieveling
Berichten: 438
Lid geworden op: 06 aug 2014 08:50
waarderingen: 99
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door Stephan »

Over de plas gaat het aandeel deze week met tientallen procenten omhoog,
kunnen we er iets achter zoeken, toch niet normaal ?!

bertje
Forum elite
Forum elite
Berichten: 6473
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1440
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door bertje »

KBC snap je toch ook niet

Celyadhield gisteren zijn webcast over 2019, waarin duidelijkheid verschaft werd over het operationeel verlies van 28,9 miljoen euro (38,2 miljoen euro in 2018). Er werd in totaal 28,2 miljoen euro cash verstookt, wat in 2020 op eenzelfde niveau zou moeten blijven. De kaspositie van 39,3 miljoen euro voldoet dus nog tot na de eerste helft van 2021. KBCS lette goed op en verlaagt vandaag het koersdoel van 23 naar 18 euro per aandeel, met ongewijzigd “Opbouwen”-advies

Koersdoel van 18, terwijl we nu 7 staan en ze spreken dan van opbouwen.

joepke
Forum newbie
Forum newbie
Berichten: 2
Lid geworden op: 04 jul 2016 23:06
waarderingen: 1
Contacteer:

Re: Celyad (voorheen Cardio3 BioSciences SA)

Bericht door joepke »

What Makes Celyad SA (CYAD) a New Buy Stock
Zacks
Zacks Equity Research
,Zacks•March 31, 2020

What Makes Celyad SA (CYAD) a New Buy Stock
More
Celyad SA (CYAD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Celyad SA basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Celyad SA, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate Revisions

Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.

Earnings Estimate Revisions for Celyad SA

For the fiscal year ending December 2020, this company is expected to earn -$2.63 per share, which is a change of -2.3% from the year-ago reported number.

Analysts have been steadily raising their estimates for Celyad SA. Over the past three months, the Zacks Consensus Estimate for the company has increased 15%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Celyad SA to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Celyad SA (CYAD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
wolfe liked last!

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie